Certican

Type: Product

Name: Certican

First reported May 20 2013 - Updated May 20 2013 - 1 reports

Novartis drug Afinitor extends time without disease progression in women with HER2+ breast cancer

Novartis drug Afinitor significantly extended time without disease progression in women with HER2 positive advanced breast cancer. It showed that Afinitor (everolimus) tablets in combination with trastuzumab (Herceptin) and vinorelbine significantly extended ... [Published PharmaBiz - May 20 2013]

Entities: Afinitor, Breast Cancer, everolimus

First reported Apr 24 2013 - Updated Apr 25 2013 - 1 reports

Novartis delivers solid performance

Novartis delivered solid performance in the first quarter, with eight key regulatory approvals and all divisions contributing to growthGroup net sales of US$14.0 billion grew 2% (+4% cc)Core operating income of US$3.7 billion (+3%, +6% cc) grew ahead ... [Published Hospital Pharmacy Europe - Apr 24 2013]

Entities: Novartis AG, US 1 Industries Inc, Arcapta Neohaler, Onbrez Breezhaler

First reported Feb 20 2013 - Updated Feb 20 2013 - 1 reports

Novartis AG

ZORTRESS (Everolimus) Tablet [Novartis Pharmaceuticals Corporation]

Updated Date: Feb 19, 2013 EST ... [Published DailyMed Drug Label Updates for the last seven ... - Feb 20 2013]

Entities: Certican, everolimus, Novartis AG

First reported Feb 18 2013 - Updated Feb 18 2013 - 2 reports

Novartis Zortress medication wins FDA nod to prevent liver transplantation rejection

The USFDA has approved Novartis Zortress as the first drug to prevent organ rejection in adult patients receiving liver transplantation in the US. ... [Published PBR - News - Feb 18 2013]

Entities: Certican, Novartis AG, Drugs

First reported Feb 18 2013 - Updated Feb 18 2013 - 1 reports

FDA Approves Everolimus for Liver Rejection

(MedPage Today) -- Everolimus (Zortress) has won FDA approval to prevent liver transplant rejection in adults, adding to its earlier similar approval in kidney transplant, according to the drug's manufacturer, Novartis. ... [Published MedPageToday.com - medical news plus CME for ph ... - Feb 18 2013]

Entities: everolimus, Certican, Novartis AG, Kidney

First reported Jan 28 2013 - Updated Jan 28 2013 - 1 reports

Time to Refill Your Prescription For Zxygjfb

The brand names of drugs are famously odd. But they seem to be getting odder. That's the conclusion of a longtime reader, who sent this along: I was recently perusing through the recent drug approval list and was struck by how strange the trade names ... [Published In the Pipeline - Jan 28 2013]

Entities: Drugs, Axolotl, Cancer, Oncology

Quotes

...population where there remains an unmet need," said Alessandro Riva, Global Head, Oncology Development & Medical Affairs, Novartis Oncology. "Everolimus works differently than any currently available treatment for HER2 positive breast cancer, and these results support its potential expanded role in advanced breast cancer."

Novartis drug Afinitor extends time without disease progression in women with HER2+ breast cancer [Published PharmaBiz - May 20 2013]

- Co. "s Zortress wins expanded FDA approval in liver patients. (Newswires) Elsewhere Co." s decision to pay upup to CHF 72mln to outgoing chairman Vasella has unleashed a wave of indignation among activist shareholders and politicians...

EUROPEAN EQUITY OPENING HEADLINES INCLUDING: ArcelorMittal steel plants may be taken over by Belg ... [Published Proactiveinvestors United Kingdom website - Feb 18 2013]

...an important milestone for patients and their transplant physicians in the US," said David Epstein, Division Head of Novartis Pharmaceuticals. "This second indication for Zortress in just three years in the US follows the recent European approval, further underscoring Novartis' continued commitment to bringing much needed treatment options to the transplant community worldwide."

US FDA approves Novartis' Zortress to prevent organ rejection in adult liver transplant patients [Published PharmaBiz - Feb 18 2013]

"Regulators want a lot of pen strokes up and down that provide a much more unique-looking name. It is more readable or interpretable if it has a lot of (Zs and Xs)" said Brannon Cashion, Addison Whitney's president

Time to Refill Your Prescription For Zxygjfb [Published In the Pipeline - Jan 28 2013]

More Content

sort by: Date \| Relevance
Novartis drug Afinitor extends time without dis... [Published PharmaBiz - May 20 2013]
Novartis drug Afinitor® significantly extended ... [Published Quoteline - May 17 2013]
Opinion/decision on a Paediatric Investigation ... [Published Opinion/decision on a Paediatric Investigation ... - May 03 2013]
Novartis delivers solid performance [Published Hospital Pharmacy Europe - Apr 24 2013]
ZORTRESS (Everolimus) Tablet [Novartis Pharmace... [Published DailyMed Drug Label Updates for the last seven ... - Feb 20 2013]
FDA Approves Everolimus for Liver Rejection [Published MedPageToday.com - medical news plus CME for ph ... - Feb 18 2013]
EUROPEAN EQUITY OPENING HEADLINES INCLUDING: Ar... [Published Proactiveinvestors United Kingdom website - Feb 18 2013]
EUROPEAN EQUITY OPENING HEADLINES INCLUDING: Ar... [Published Proactiveinvestors United Kingdom RSS feed - Feb 18 2013]
Novartis Zortress medication wins FDA nod to pr... [Published PBR - News - Feb 18 2013]
US FDA approves Novartis' Zortress to prevent o... [Published PharmaBiz - Feb 18 2013]
Novartis drug Zortress® is first in over a deca... [Published PR Newswire: Health - Feb 15 2013]
Time to Refill Your Prescription For Zxygjfb [Published In the Pipeline - Jan 28 2013]
Thermo Fisher introduces CE marked QMS Everolim... [Published PharmaBiz - Jan 16 2013]
Phase III data shows Novartis drug Afinitor ben... [Published PharmaBiz - Jan 12 2013]
Methods for detection of hydrophobic drugs [Published PharmCast - Jan 01 2013]
European Commission approves Novartis' Votubia ... [Published PharmaBiz - Nov 06 2012]